Viromed conducts phase I clinical trial for VM202 in China

Published: 2008-12-16 06:40:00

Updated: 2008-12-16 06:40:00

The phase I clinical trial with VM202, a gene-based medicine for treatment of cardiovascular disease (CVD), has been conducted by ViroMed’s China partner Beijing Northland Biotech for peripheral artery disease (PAD, a form of CVD affecting limbs) such as critical limb disease from diabetes and ha...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK